Sedatives for Anxiety with Lacerations in Children
(ALICE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to identify the best light sedative for reducing anxiety in children during laceration repairs. Researchers will compare three treatments: dexmedetomidine (also known as Precedex) and midazolam, both administered as a nasal spray, and nitrous oxide, which is inhaled. The trial seeks children aged 2 to 12 who need stitches for simple cuts and whose caregivers prefer a sedative to help keep them calm. As a Phase 3 trial, this study represents the final step before FDA approval, offering a chance to contribute to a treatment that could soon become widely available.
Will I have to stop taking my current medications?
The trial requires that participants do not take any sedative, anxiolytic, or alpha-2-adrenergic receptor agonist within 24 hours before the intervention. This means you may need to stop certain medications that fall into these categories before participating.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Previous studies have shown that intranasal dexmedetomidine is a safe sedative for children, keeping them calm without major side effects. One study found it did not cause nasal irritation, a common issue with similar drugs. Intranasal midazolam is also considered safe for children, calming them before procedures with minimal to moderate side effects. Research indicates it works well for treating cuts, making it a suitable option for these situations.
Inhaled nitrous oxide, a gas that helps children relax, has a strong safety record. Large studies report no major side effects. It is often used in dental procedures to reduce anxiety and is considered both safe and effective.
These treatments have been thoroughly researched and are generally well-tolerated, making them promising options for reducing distress in children during cut repairs.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for anxiety in children with lacerations because they offer unique approaches. Intranasal dexmedetomidine and midazolam provide sedation through easy-to-administer nasal sprays, which can be less intimidating for kids compared to traditional intravenous methods. Dexmedetomidine, in particular, is notable for its sedative and pain-relief properties without causing significant respiratory depression. Inhaled nitrous oxide stands out for its fast-acting and reversible effects, offering a quick way to reduce anxiety and pain in a non-invasive manner. These options promise a gentler experience for children needing quick relief during minor medical procedures.
What evidence suggests that this trial's treatments could be effective for reducing distress during laceration repair in children?
In this trial, participants will receive one of three treatments to help calm children before medical procedures. Research has shown that intranasal dexmedetomidine, a nose spray included in this trial, can effectively calm children and is often used by doctors when treating cuts. Another treatment option is intranasal midazolam, which also reduces anxiety in children during minor procedures, though some may still feel anxious, and it can irritate the nose. The third option, inhaled nitrous oxide, or "laughing gas," is well-known for easing anxiety and pain during procedures, and parents generally approve of its use. Each option can help calm children during medical treatments, with varying levels of success.34567
Are You a Good Fit for This Trial?
This trial is for children aged 2 to nearly 13 years who need stitches for a single cut and don't require heavy sedation. The child or caregiver must want mild sedation, which will be given alongside local anesthesia. Kids with certain heart rates or blood pressure issues, suspected pregnancy, inability to express pain, language barriers without an interpreter, over 65 kg in weight, not healthy or with controlled disease only (ASA class I/II), drug allergies or recent sedatives can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preparation and Treatment
Participants receive anxiolytic treatment (IN dexmedetomidine, IN midazolam, or N2O) for laceration repair
Recovery
Participants are monitored post-procedure for any immediate adverse effects and satisfaction is assessed
Follow-up
Participants are monitored for late maladaptive behaviors and any adverse effects up to 72 hours post-discharge
What Are the Treatments Tested in This Trial?
Interventions
- Dexmedetomidine
- Midazolam Nasal Spray
- Nitrous oxide
Dexmedetomidine is already approved in European Union, United States, Canada, Japan for the following indications:
- Sedation in intensive care settings
- Procedural sedation
- Sedation in intensive care settings
- Procedural sedation
- Sedation in intensive care settings
- Procedural sedation
- Sedation in intensive care settings
- Procedural sedation
Find a Clinic Near You
Who Is Running the Clinical Trial?
London Health Sciences Centre OR Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's
Lead Sponsor
Lawson Health Research Institute
Lead Sponsor